medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2012, Number 4

<< Back Next >>

Acta Med 2012; 10 (4)

Melanoma. Diagnosis and therapeutic basis

Gallegos HJF

Language: Spanish
References: 42
Page: 207-213
PDF size: 343.61 Kb.


ABSTRACT

Melanoma is the third most common cancer in the skin but it is the neoplasia with the greatest impact on mortality, its etiology is multifactorial and has been reported that its prevalence has increased in the last two decades. In Mexico ranks seventh in frequency among all malignancies and 80% of cases are in locally advanced stages. The prognosis depends on the stage. Prognostic factors with greatest impact in survival are nodal status, tumor thickness, ulceration and, in thin or intermediate melanomas, the mitotic index. The diagnostic approach is of great importance to achieve adequate treatment; adherence to global standards of treatment and guidelines allows us to obtain the best rates of loco-regional control, first target to be achieved in patients with cutaneous melanoma.The aim of this manuscript is to provide a synthesis of the most important aspects in the diagnosis and treatment of cutaneous melanoma, based on current evidence obtained in the literature.


REFERENCES

  1. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Selftor EA, Selftor RE et al. Reprograming metastatic melanoma cells to assume a neural cresta cell-like phenotype in an embruonic microenviroment. Proc Natl Acad Sci USA 2006; 103: 3752-3757.

  2. Puig S, Puig-Butille JA, Badenas C, Cuellar F, Malvehy. Novedades genéticas en melanoma. Piel 2006; 21: 272-274.

  3. De la Fuente García A, Ocampo Candiani J. Melanoma cutáneo. Gac Med Mex 2010; 146: 126-135.

  4. Gallegos-Hernández JF. Melanoma cutáneo. La importancia de la foto-protección y del diagnóstico oportuno. Cir Cir 2008; 76: 363-366.

  5. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349: 2233-2240.

  6. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006; 32: 481-492.

  7. Fernández-Flores A. Prognostic factors for melanoma progresión and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol 2012; 53: 449-459.

  8. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.

  9. Balch CM, Gershenwald JE, Soong SJ. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.

  10. Edge SB, Carducci M, Byrd DR, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag, LLC; 2009.

  11. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579-586.

  12. Francken AB, Shaw HM, Thompson JF. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426-433.

  13. Azzola MF, Shaw HM, Thompson JF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498.

  14. Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108.

  15. Paek SC, Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108.

  16. Gimotty PA, Elder DE, Fraker DL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-1134.

  17. Cascinelli N, Belli F, Santinami M. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000; 7: 469-474.

  18. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A et al. Sentinel lymph node biopsy for melanoma; American Society of Clinical Oncology and Society of Clinical Oncology and Society of Surgical Oncology Joint clinical practice guideline. J Clin Oncol 2012; 30: 2912-2918.

  19. Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Fend F, Hantschke M et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations of general practice. J Dtsch Dermatol Ges 2011; 9: 690-699.

  20. Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.

  21. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011; 18: 506-513.

  22. Buzaid AC, Tinoco L, Ross MI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13: 2104-2108.

  23. Clark PB, Soo V, Kraas J et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006; 141: 284-288.

  24. Maubec E, Lumbroso J, Masson F et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007; 17: 147-154.

  25. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-441.

  26. Balch CM, Urist MM, Karakousis CP. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-267.

  27. Cohn-Cedermark G, Rutqvist LE, Andersson R. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with coetaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.

  28. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941-1946.

  29. Thomas JM, Newton-Bishop J, A’Hern R et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766.

  30. 30. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46: 419-426.

  31. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label studyin 32 patients. Arch Dermatol 2008; 144: 943-945.

  32. Gallegos-Hernández JF, Martínez-Gómez H y Flores-Díaz R. La disección radical de cuello en cáncer de vías aerodigestivas superiores. Indicaciones, extensión y radicalidad. Cir Cir 2002; 70: 369-376.

  33. Pasquiali S, Spillane AJ, de Wilt JH, McCaffery K, Rossi CR, Quinn MJ et al. Surgeons’ opinions on lymhadenectomy in melanoma patients with positive sentinel nodes: A worldwide web-based suvey. Ann Surg Oncol 2012; 19: 4322-4329.

  34. Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caracó C et al. EANM-EORTC general recomendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009; 36: 1713-1742.

  35. Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozillo N et al. The impacto n morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicenter selective lymphadenectomy trial (I). Ann Surg Oncol 2010; 17: 3324-3329.

  36. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, ESMO working Group. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: 86-91.

  37. Ulrich J, van Akkoi AJ, Eggermont AM, Voit C. New developments in melanoma: utility of ultrasound (inicial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther 2011; 11: 1693-701.

  38. Pilko G, Besic N, Zgajnar J, Hocevar M. Melanoma patients with ultrasonically negative regional lymph node basins have a lower tumour burden in regional lymph nodes. In: ESSOmeeting. Bordeaux: [s.e.]; 2010. Available in: http://www.essoweb.org/data/esso2010/poster/Read_Abstract.php?Id=262

  39. Gallegos-Hernández JF. Melanoma; estadificación. Cáncer&Piel 2012; 9: 3-12

  40. Agrawal S, Kane JM, 3rd, Guadagnolo BA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-5844.

  41. Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.

  42. Chapman PB, Hauschild A, Robert C. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.




2020     |     www.medigraphic.com